Bispecific nanobodies – promising engineered candidates with high therapeutic efficiency
Authors:
- Sneha BanerjeeSBSneha Banerjee
- Sreeja VangapallySVSreeja Vangapally
- Anna MariyaAMAnna Mariya
- Bhaskar PaidimuddalaBPBhaskar Paidimuddala
- 25 January 2026
- journal article
- Published by Elsevier in Journal of Biotechnology
- Vol. 411, 102-115
Abstract
No abstract availableFunding Information
- India Ministry of Science & Technology Department of Science and Technology (ANRF/ECRG/2024/000531/LS)
- Anusandhan National Research Foundation
This publication has 128 references indexed in Scilit:
- Targeting intracellular cancer proteins with tumor‐microenvironment‐responsive bispecific nanobody‐PROTACs for enhanced therapeutic efficacyMedcomm, 2025
- Development of a highly sensitive immunoassay based on pentameric nanobodies for carcinoembryonic antigen detectionAnalytica Chimica Acta, 2023
- Role of a noncanonical disulfide bond in the stability, affinity, and flexibility of a VHH specific for the Listeria virulence factor InlBProtein Science, 2020
- The Therapeutic Potential of NanobodiesBioDrugs, 2019
- Caplacizumab: First Global ApprovalDrugs, 2018
- A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growthInternational Journal of Cancer, 2011
- Properties, production, and applications of camelid single-domain antibody fragmentsApplied Microbiology and Biotechnology, 2007
- Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritisArthritis & Rheumatism, 2006
- Prokaryotic expression of antibodiesCancer and Metastasis Reviews, 2005
- Length distribution of CDRH3 in antibodiesProteins: Structure, Function, and Bioinformatics, 1993